全文获取类型
收费全文 | 70919篇 |
免费 | 5262篇 |
国内免费 | 2482篇 |
出版年
2023年 | 1140篇 |
2022年 | 1060篇 |
2021年 | 2227篇 |
2020年 | 2349篇 |
2019年 | 3264篇 |
2018年 | 2837篇 |
2017年 | 2022篇 |
2016年 | 2011篇 |
2015年 | 2514篇 |
2014年 | 4743篇 |
2013年 | 5894篇 |
2012年 | 3653篇 |
2011年 | 4693篇 |
2010年 | 3573篇 |
2009年 | 3868篇 |
2008年 | 3942篇 |
2007年 | 3968篇 |
2006年 | 3520篇 |
2005年 | 3053篇 |
2004年 | 2704篇 |
2003年 | 2147篇 |
2002年 | 1927篇 |
2001年 | 1223篇 |
2000年 | 937篇 |
1999年 | 918篇 |
1998年 | 855篇 |
1997年 | 638篇 |
1996年 | 586篇 |
1995年 | 612篇 |
1994年 | 565篇 |
1993年 | 431篇 |
1992年 | 431篇 |
1991年 | 356篇 |
1990年 | 293篇 |
1989年 | 241篇 |
1988年 | 211篇 |
1987年 | 184篇 |
1986年 | 161篇 |
1985年 | 272篇 |
1984年 | 455篇 |
1983年 | 334篇 |
1982年 | 347篇 |
1981年 | 264篇 |
1980年 | 201篇 |
1979年 | 194篇 |
1978年 | 172篇 |
1977年 | 143篇 |
1976年 | 115篇 |
1975年 | 108篇 |
1973年 | 104篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
991.
Xinming Du Jiawen Qian Yujie Wang Mingming Zhang Yiwei Chu Yingxia Li 《Bioorganic & medicinal chemistry》2019,27(13):2784-2800
Toll-like receptor 2 (TLR2) is a bridge between innate immunity and adaptive immunity. TLR2 agonists have been exploited as potential vaccine adjuvants and antitumor agents. However, no TLR2 agonists have been approved by FDA up to now. To discover drug-like TLR2 selective agonists, a novel series of Pam3CSK4 derivatives were designed based on the crystal structure of hTLR2-hTLR1-Pam3CSK4 complex, synthesized and evaluated for their immune-stimulatory activities. Among them, 35c was identified as a murine-specific TLR2 agonist, while 35f was a human-specific TLR2 agonist. Besides, 35d (human and murine TLR2 agonist) showed TLR2 agonistic activity comparable to Pam3CSK4, which included: elevated IL-6 expression level (EC50 = 83.08 ± 5.94 nM), up-regulated TNF-α and IL-6 mRNA expression and promoted maturation of DCs through activating the NF-κB signaling pathway. TLRs antibodies test showed that 35a and 35d were TLR2/1 agonists, while 35f was a TLR2/6 agonist. 相似文献
992.
Woong-Hee Kim Pyeonghwa Jeong Seon-Wook Kim Haaglim Cho Jeong-min Lee Shinae Seo Haihong Shen Youngkeun Ahn Da-Woon Jung Yong-Chul Kim Darren R. Williams 《Bioorganic & medicinal chemistry》2019,27(13):2923-2934
Indirubin-based compounds affect diverse biological processes, such as inflammation and angiogenesis. In this study, we tested a novel indirubin derivative, LDD-1819 (2-((((2Z,3E)-5-hydroxy-5′-nitro-2′-oxo-[2,3′-biindolinylidene]-3-ylidene)amino)oxy)ethan-1-aminium chloride) for two major biological activities: cell plasticity and anti-cancer activity. Biological assays indicated that LDD-1819 induced somatic cell plasticity. LDD-1819 potentiated myoblast reprogramming into osteogenic cells and fibroblast reprogramming into adipogenic cells. Interestingly, in an assay of skeletal muscle dedifferentiation, LDD-1819 induced human muscle cellularization and blocked residual proliferative activity to produce a population of mononuclear refractory cells, which is also observed in the early stages of limb regeneration in urodele amphibians. In cancer cell lines, LDD-1819 treatment inhibited cell invasion and selectively induced apoptosis compared to normal cells. In an animal tumor xenograft model, LDD-1819 reduced human cancer cell metastasis in vivo at doses that did not produce toxicity. Biochemical assays showed that LDD-1819 possessed inhibitory activity against glycogen synthase kinase-3β, which is linked to cell plasticity, and aurora kinase, which regulates carcinogenesis. These results indicate that novel indirubin derivative LDD-1819 is a dual inhibitor of glycogen synthase kinase-3β and aurora A kinase, and has potential for development as an anti-cancer drug or as a reprogramming agent for cell-therapy based approaches to treat degenerative diseases. 相似文献
993.
The most common inflammatory disease of the airways is asthma among children affecting around 235 million people worldwide. 5-Lipoxygenase (5-LOX) is a crucial enzyme which helps in the conversion of arachidonic acid (AA) to leukotrienes (LTs), the lipid mediators. It is associated with several inflammation related disorders such as asthma, allergy, and atherosclerosis. Therefore, it is considered as a promising target against inflammation and asthma. Currently, the only drug against 5-LOX which is available is Zileuton, while a few inhibitors are in clinical trial stages such as Atreleuton and Setileuton. So, there is a dire requirement in the area of progress of novel 5-LOX inhibitors which necessitates an understanding of their structure activity relationship and mode of action. In this review, novel 5-LOX inhibitors reported so far, their structural design, SAR and developmental strategies along with clinical updates are discussed over the last two decades. 相似文献
994.
《Bioorganic & medicinal chemistry》2019,27(16):3546-3550
Previously we have reported on a series of pyridine-3-carboxamide inhibitors of DNA gyrase and DNA topoisomerase IV that were designed using a computational de novo design approach and which showed promising antibacterial properties. Herein we describe the synthesis of additional examples from this series aimed specifically at DNA gyrase, along with crystal structures confirming the predicted mode of binding and in vitro ADME data which describe the drug-likeness of these compounds. 相似文献
995.
996.
997.
Ho Shin Kim Van-Hai Hoang Mannkyu Hong Kyung Chul Kim Jihyae Ann Cong-Truong Nguyen Ji Hae Seo Hoon Choi Jun Yong Kim Kyu-Won Kim Woong Sub Byun Sangkook Lee Seungbeom Lee Young-Ger Suh Jie Chen Hyun-Ju Park Tae-Min Cho Ji Young Kim Jeewoo Lee 《Bioorganic & medicinal chemistry》2019,27(7):1370-1381
On the basis of deguelin, a series of the B,C-ring truncated surrogates with N-substituted amide linkers were investigated as HSP90 inhibitors. The structure activity relationship of the template was studied by incorporating various substitutions on the nitrogen of the amide linker and examining their HIF-1α inhibition. Among them, compound 57 showed potent HIF-1α inhibition and cytotoxicity in triple-negative breast cancer lines in a dose-dependent manner. Compound 57 downregulated expression and phosphorylation of major client proteins of HSP90 including AKT, ERK and STAT3, indicating that its antitumor activity was derived from the inhibition of HSP90 function. The molecular modeling of 57 demonstrated that 57 bound well to the C-terminal ATP-binding pocket in the open conformation of the hHSP90 homodimer with hydrogen bonding and pi-cation interactions. Overall, compound 57 is a potential antitumor agent for triple-negative breast cancer as a HSP90 C-terminal inhibitor. 相似文献
998.
999.
Yumin Dai Ashley N. Peralta Jessica E. Wynn Chringma Sherpa Hao Li Astha Verma Stuart F.J. Le Grice Webster L. Santos 《Bioorganic & medicinal chemistry》2019,27(8):1759-1765
Interaction of HIV-1 rev response element (RRE) RNA with its cognate protein, Rev, is critical for HIV-1 replication. Understanding the mode of interaction between RRE RNA and ligands at the binding site can facilitate RNA molecular recognition as well as provide a strategy for developing anti-HIV therapeutics. Our approach utilizes branched peptides as a scaffold for multivalent binding to RRE IIB (high affinity rev binding site) with incorporation of unnatural amino acids to increase affinity via non-canonical interactions with the RNA. Previous high throughput screening of a 46,656-member library revealed several hits that bound RRE IIB RNA in the sub-micromolar range. In particular, the lead compound, 4B3, displayed a Kd value of 410?nM and demonstrated selectivity towards RRE. A ribonuclease protection assay revealed that 4B3 binds to the stem-loop structure of RRE IIB RNA, which was confirmed by SHAPE analysis with 234 nt long NL4-3 RRE RNA. Our studies further indicated interaction of 4B3 with both primary and secondary Rev binding sites. 相似文献
1000.
Iwona Popiołek Anna Niziołek Kamil Kamiński Urszula Kwolek Maria Nowakowska Krzysztof Szczubiałka 《Bioorganic & medicinal chemistry》2019,27(7):1414-1420
A cationic derivative of γ-cyclodextrin (GCD) modified with propylenediamine (PDA) was synthesized. It was shown that the derivative (GCD–PDA) is mucoadhesive and resistant to the digestion with?∝-amylase indicating that it may constitute an efficient oral delivery vehicle. GCD-PDA formed an inclusion complex with berberine (BBR), an alkaloid displaying a multitude of beneficial physiological effects. The complexed BBR penetrates a lipid membrane easier than the free one. Both uncomplexed BBR and that complexed with GCD-PDA was delivered to normal (NMuMG) and cancerous (4T1) murine mammary gland cells. In the normal cells both free and complexed BBR was homogeneously dispersed in the cytoplasm and was nontoxic up to 131?μM. In the cancerous cells uncomplexed BBR was also homogeneously dispersed but it was toxic to about 25% of cells at 131?μM, while the GCD-PDA/BBR complex was preferably localized in lysosomes and its toxicity doubled at this concentration compared to that of free BBR. Moreover, free BBR and GCD-PDA/BBR showed even more efficient inhibitory effect against murine melanoma (B16-F10) cells than against 4T1 cells. 相似文献